1. Current Graft-versus-Host Disease–Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant 
Scott R. Solomon, Connie Sizemore, Xu Zhang, Michelle Ridgeway, Melhem Solh, Lawrence E. Morris, H. Kent Holland, Asad Bashey 
Biology of Blood and Marrow Transplantation 
Volume 23, Issue 7, Pages (July 2017)
DOI: /j.bbmt
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1 Possible transitions in multistate model for CGRFS.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
(A) Comparison of CGRFS to conventional GRFS, DFS, and OS, (B) Gain in CGRFS due to the treatment of chronic GVHD as a dynamic event.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3 Component events of the CGRFS endpoint.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4
CGRFS according to (A) DRI, (B) age, (C) HCT-CI, (D) donor type, (E) conditioning intensity, and (F) stem cell source.
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2017 The American Society for Blood and Marrow Transplantation Terms and Conditions